Affinage

Showing P2RY1 — P2Y1 is a alias.

P2RY1

P2Y purinoceptor 1 · UniProt P47900

Length
373 aa
Mass
42.1 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 40 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

P2RY1 (P2Y1R) is a Gq-coupled G-protein-coupled receptor for extracellular ADP that converts purinergic signals into PLC-IP3-Ca2+ mobilization and broad downstream kinase activation across platelets, vasculature, and the nervous system (PMID:9038354, PMID:14742685, PMID:11278310). Reconstitution of purified receptor with heterotrimeric Gq confirms direct agonist-stimulated GTP hydrolysis with the rank order 2MeSADP > ADP >> ATP, establishing ADP as the physiological full agonist and ATP as a low-potency partial agonist/competitive antagonist (PMID:9547364, PMID:14742685). Crystallography resolved two distinct ligand pockets—an orthosteric site within the transmembrane bundle occupied by nucleotide antagonists and an allosteric pocket on the receptor–lipid interface bound by BPTU—and these sites translate into distinct, pathway-dependent antagonist pharmacology (PMID:25822790, PMID:28864555). Downstream of Gq, P2Y1R drives ERK1/2, JNK, and p38 signaling to Elk-1-dependent transcription, Rac/RhoA-dependent cytoskeletal remodeling, and EGFR transactivation (PMID:11278310, PMID:12805285, PMID:16194206, PMID:18057028). Receptor activity is shaped at multiple levels: ectonucleotidases (NTPDase1/2) set local agonist availability and desensitization state (PMID:15590415, PMID:20067476, PMID:15496502), PKC mediates desensitization and frequency-dependent negative feedback via C-terminal Thr339 (PMID:15665114, PMID:12805284), and trafficking is governed by ALIX/YPX3L-directed ubiquitin-independent lysosomal sorting and SNX1-regulated slow recycling (PMID:27301021, PMID:20070609). The receptor constitutively homodimerizes through a C-terminal DTSL/NHERF-2 interaction required for internalization, and hetero-oligomerizes with P2Y11 to redirect its trafficking and ligand selectivity (PMID:17824841, PMID:18270199). Physiologically, P2Y1R is essential and non-redundant for ADP-induced platelet shape change, aggregation, Ca2+ mobilization, and Rac/RhoA activation, while a separate receptor (P2Y12) couples ADP to adenylyl cyclase inhibition (PMID:9639511, PMID:16194206, PMID:11341507); it mediates fast inhibitory purinergic neurotransmission controlling colonic motility (PMID:22371476, PMID:25341729), astrocytic glutamate exocytosis and GABA-transporter regulation (PMID:16882655, PMID:24733747), and thermal nociception, undergoing inflammation-induced upregulation that drives heat sensitization (PMID:21310055, PMID:22137295).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1997 High

    Established the molecular identity of the platelet ADP receptor by showing the cloned P2Y1 receptor is an ADP-activated, calcium-mobilizing GPCR, resolving which gene transduces ADP-evoked Ca2+ signals.

    Evidence Heterologous expression in Jurkat cells with HPLC-purified nucleotide pharmacology and platelet RT-PCR

    PMID:9038354

    Open questions at the time
    • Did not resolve which receptor couples ADP to adenylyl cyclase inhibition
    • Coupling partner (Gq) inferred pharmacologically, not biochemically
  2. 1998 High

    Clarified the true agonist/antagonist profile by removing nucleotide contamination, demonstrating ADP is the full agonist and ATP a competitive antagonist, and that selective antagonists block platelet aggregation/Ca2+ but not adenylyl cyclase inhibition—splitting the platelet ADP response into two receptors.

    Evidence Purity-controlled pharmacology in endothelial and Jurkat cells, plus selective antagonists in human platelets with fura-2 imaging

    PMID:9547364 PMID:9639511

    Open questions at the time
    • Identity of the second adenylyl-cyclase-coupled ADP receptor not yet established
    • Antagonist binding residues not mapped
  3. 1998 High

    Localized the antagonist/nucleotide binding determinants to specific transmembrane residues, providing the first structural model of where ligands engage the receptor.

    Evidence Site-directed mutagenesis with PLC functional readout and rhodopsin-based molecular modeling

    PMID:9554879

    Open questions at the time
    • Model based on rhodopsin homology, not direct structure
    • Agonist binding mode not resolved
  4. 2001 High

    Defined the downstream kinase architecture, showing P2Y1R activates ERK1/2 and JNK (but not p38) through PI3K/Src/PKC-Ras inputs converging on Elk-1, with a JNK limb driving apoptosis.

    Evidence Dominant-negative Ras/MKK4, kinase inhibitors, pertussis toxin, and caspase-3 assays in stable cell lines

    PMID:11278310

    Open questions at the time
    • Cell-type generality of the apoptotic JNK limb unclear
    • Direct effector linkages inferred pharmacologically
  5. 2004 High

    Proved direct Gq coupling biochemically by reconstituting purified receptor with heterotrimeric Gq, fixing the agonist rank order under conditions that prevent nucleotide metabolism.

    Evidence Receptor purification from Sf9, proteoliposome reconstitution, radioligand binding, and steady-state GTPase assays

    PMID:14742685

    Open questions at the time
    • Other G-protein couplings not tested in this system
    • Lipid/allosteric modulation not addressed
  6. 2004 High

    Revealed an intrinsic voltage sensitivity of P2Y1R that potentiates IP3-dependent Ca2+ release independent of voltage-gated channels, expanding the receptor's signaling repertoire.

    Evidence Patch clamp with fura-2 in megakaryocytes from P2Y1-knockout mice, with GTPgammaS/AlF4- dialysis controls

    PMID:15528188

    Open questions at the time
    • Structural basis of voltage sensing not identified
    • Physiological relevance outside megakaryocytes unclear
  7. 2005 High

    Distinguished P2Y1 desensitization mechanism from P2Y12, showing it is PKC-dependent rather than GRK-mediated.

    Evidence Dominant-negative GRK, GRK siRNA, and PKC inhibition in platelets and 1321N1 cells

    PMID:15665114

    Open questions at the time
    • PKC phosphorylation site(s) not yet mapped here
    • Arrestin involvement not directly assessed
  8. 2005 High

    Assigned the Rac-activating limb of platelet ADP signaling to P2Y1R via Gq, linking the receptor to PAK and actin polymerization independently of P2Y12 and PI3K.

    Evidence Rac-GTP pulldowns, selective antagonists, P2Y1-knockout platelets, and PAK/actin assays

    PMID:16194206

    Open questions at the time
    • Identity of the GEF coupling Gq to Rac not defined
  9. 2008 High

    Mapped the determinants of receptor oligomerization and trafficking, showing constitutive/agonist-induced homodimerization via the C-terminal DTSL motif and NHERF-2 is required for internalization but not activation, and that P2Y1 hetero-oligomerizes with P2Y11 to control its endocytosis and ligand selectivity.

    Evidence Live-cell FRET, C-terminal deletion mutants, co-IP/co-pulldown, and siRNA rescue in HEK293/1321N1 cells

    PMID:17824841 PMID:18270199

    Open questions at the time
    • Stoichiometry of higher-order oligomers unresolved
    • In vivo relevance of P2Y1-P2Y11 heteromers not shown
  10. 2016 Medium

    Defined the post-activation degradative fate of P2Y1R as a ubiquitin-independent ALIX/YPX3L-dependent lysosomal sorting pathway, complementing an earlier SNX1-regulated slow recycling route.

    Evidence ALIX siRNA, YPX3L motif mutagenesis, and degradation/recycling microscopy; SNX1 and retromer manipulation

    PMID:20070609 PMID:27301021

    Open questions at the time
    • Switch between recycling and degradation fates not defined
    • Single-lab findings for each trafficking route
  11. 2015 High

    Provided atomic-resolution structures revealing two spatially distinct ligand pockets—orthosteric (intra-helical) and allosteric (lipid-interface)—establishing a structural basis for the receptor's dual antagonist pharmacology.

    Evidence X-ray crystallography of MRS2500 and BPTU complexes, with all-atom MD simulations of the activation mechanism

    PMID:25822790 PMID:27460867

    Open questions at the time
    • No active-state agonist-bound or Gq-coupled structure
    • MD activation model lacks mutagenesis validation
  12. 2017 Medium

    Demonstrated that allosteric vs orthosteric antagonism produces pathway- and agonist-biased blockade, refining how the two binding sites translate into functional pharmacology.

    Evidence ERK1/2, GTPgammaS, beta-arrestin2, and label-free assays with multiple agonists and antagonists

    PMID:28864555

    Open questions at the time
    • Structural basis of probe dependence not resolved
    • Single-lab dataset
  13. 2014 High

    Identified physiological purinergic neurotransmitters and gut function for P2Y1R, showing it mediates fast inhibitory junction potentials and Up4A-evoked relaxation controlling colonic motility.

    Evidence P2ry1-knockout mice with intracellular electrophysiology, contractility, transit imaging, and heterologous Ca2+ assays

    PMID:22371476 PMID:25341729

    Open questions at the time
    • Source and regulation of endogenous beta-NAD/Up4A release not fully defined
  14. 2014 High

    Established astrocytic and glial roles for P2Y1R, coupling it to regulated glutamate exocytosis (via TNFalpha/PGE2), GABA-transporter inhibition, and PKC-gated Ca2+ oscillation feedback at C-terminal Thr339.

    Evidence TIRF vesicle imaging, knockout mice, PLC/Ca2+ chelation controls, and C-terminal mutagenesis in primary astrocytes

    PMID:12805284 PMID:16882655 PMID:24733747

    Open questions at the time
    • Integration of these glial outputs in intact circuits incompletely defined
  15. 2011 High

    Defined a sensory role, showing P2Y1R is required for normal thermal nociceptor sensitivity and that inflammation-driven upregulation mediates heat sensitization.

    Evidence P2Y1-knockout mice and in vivo DRG siRNA with ex vivo skin-nerve recording and DRG calcium imaging

    PMID:21310055 PMID:22137295

    Open questions at the time
    • Molecular link between P2Y1 and TRPV1-channel modulation not fully resolved
    • Inflammation upregulation mechanism not defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the two structurally defined ligand sites, oligomerization state, and ectonucleotidase-set agonist microenvironment integrate to dictate biased signaling and tissue-specific output in vivo remains unresolved.
  • No active-state structure with Gq
  • No unified model linking dimerization/heteromerization to signaling bias in native tissue
  • Determinants of recycling-vs-degradation fate undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3
Localization
GO:0005886 plasma membrane 3 GO:0005768 endosome 2 GO:0005764 lysosome 1
Pathway
R-HSA-109582 Hemostasis 3 R-HSA-112316 Neuronal System 3 R-HSA-162582 Signal Transduction 3
Partners
NHERF2P2RY11PDCD6IPSNX1

Evidence

Reading pass · 40 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 Crystal structures of human P2Y1R revealed two distinct ligand-binding sites: nucleotide antagonist MRS2500 binds within the seven transmembrane bundle (orthosteric site, distinct in shape and location from P2Y12R), while non-nucleotide antagonist BPTU binds an allosteric pocket on the external receptor–lipid bilayer interface entirely outside the helical bundle. X-ray crystallography at 2.7 Å (MRS2500 complex) and 2.2 Å (BPTU complex) Nature High 25822790
2016 All-atom MD simulations (20 µs total) showed that ADP activates P2Y1R by breaking an ionic lock within the receptor and forming a continuous water channel, while BPTU acts as an antagonist by stabilizing extracellular helix bundles and increasing lipid order, and MRS2500 blocks signaling by occupying the orthosteric binding site. Long-timescale all-atom molecular dynamics simulations (20 µs) Angewandte Chemie International Edition Medium 27460867
1997 Human P2Y1 receptor expressed in Jurkat cells functions as an ADP receptor coupled to intracellular calcium mobilization; 2-methylthio-ADP is the most potent agonist, ADP is a full agonist, and ATP acts as a competitive antagonist. The receptor is expressed in platelets and megakaryoblastic cells, identifying it as the platelet P2T purinoceptor. Heterologous expression in Jurkat cells with HPLC-purified nucleotide agonist/antagonist pharmacology; RT-PCR in platelets and megakaryoblastic cell lines FEBS letters High 9038354
1998 P2Y1 receptor is an ADP-specific Gq-coupled receptor; when ATP contamination is removed by creatine phosphate/creatine phosphokinase treatment, purified 2-MeSATP and 2-ClATP act as competitive antagonists (not agonists) at both rat and human P2Y1 receptors, demonstrating ATP is a competitive antagonist. Pharmacological assays with creatine phosphate/creatine phosphokinase nucleotide purity control in endothelial cells and P2Y1-transfected Jurkat cells Molecular pharmacology High 9547364
1998 Selective P2Y1 competitive antagonists A2P5P and A3P5P inhibit ADP-induced platelet shape change, aggregation, and calcium mobilization but do not affect ADP-induced inhibition of adenylyl cyclase in platelets, demonstrating P2Y1 is necessary for ADP-induced platelet aggregation and calcium mobilization but a separate ADP receptor couples to adenylyl cyclase. Pharmacological antagonism with selective P2Y1 antagonists in human platelets and P2Y1-expressing Jurkat cells; fura-2 calcium measurements Blood High 9639511
1998 Site-directed mutagenesis of the human P2Y1 receptor identified key residues for antagonist binding: F226A, K280A, and Q307A mutations in transmembrane helices 5, 6, and 7 abolished antagonist MRS2179 potency; H132, T222, and Y136 had modulatory roles. A rhodopsin-based molecular model localized the nucleotide binding site to TM regions 3, 6, and 7. Site-directed mutagenesis of transmembrane domain residues combined with functional assay (phospholipase C stimulation) and computational molecular modeling Journal of medicinal chemistry High 9554879
2004 Purified human P2Y1 receptor reconstituted in proteoliposomes with heterotrimeric Gq(alpha)beta1gamma2 directly stimulates GTP hydrolysis upon agonist addition (up to 50-fold with 2MeSADP plus RGS4). Agonist affinity order under conditions preventing nucleotide metabolism: 2MeSADP > ADP = 2MeSATP = ATPalphaS = ADPbetaS >> ATP. ATP is a partial agonist with 20-fold lower potency than ADP. Receptor purification from baculovirus/Sf9 system; reconstitution in proteoliposomes with purified heterotrimeric G proteins; radioligand binding ([3H]MRS2279); steady-state GTP hydrolysis Molecular pharmacology High 14742685
2005 P2Y1 receptor desensitization in platelets and 1321N1 cells is mediated by protein kinase C, not by GRK2 or GRK6. In contrast, P2Y12 desensitization requires GRKs. Dominant-negative GRK mutants and GRK siRNA did not affect P2Y1 desensitization, while PKC inhibition abolished it. Dominant-negative GRK mutant overexpression; GRK-specific siRNA knockdown; PKC inhibition; platelet aggregation and calcium mobilization assays Blood High 15665114
2008 P2Y11 receptor forms hetero-oligomers with P2Y1 receptor when co-expressed in HEK293 cells, detected by co-pulldown, co-immunoprecipitation, and FRET. This interaction promotes agonist-induced internalization of P2Y11 (which cannot undergo endocytosis alone), and alters the ligand selectivity of P2Y11. Endogenous P2Y1 in HEK293 cells supports GFP-P2Y11 endocytosis, abolished by P2Y1 siRNA. Co-pulldown, co-immunoprecipitation, FRET; siRNA knockdown; fluorescence microscopy of receptor internalization in 1321N1 and HEK293 cells The Biochemical journal High 17824841
2016 After agonist activation, P2Y1 is sorted to lysosomes for degradation via a ubiquitin-independent pathway requiring a YPX3L motif in the second intracellular loop that binds the adaptor protein ALIX. Depletion of ALIX or mutation of the YPX3L motif blocks P2Y1 sorting into multivesicular endosome lumens and prevents lysosomal degradation. ALIX siRNA depletion; site-directed mutagenesis of YPX3L motif; fluorescence microscopy tracking lysosomal sorting; degradation assays PloS one High 27301021
2010 P2Y1 receptor recycling occurs via a slow retromer-independent pathway regulated by sorting nexin 1 (SNX1). SNX1 inhibition dramatically increased the rate of P2Y1 receptor recycling, while inhibition of retromer components Vps26 and Vps35 had no effect. P2Y12 receptor returns to the cell surface via a rapid SNX1-independent route. SNX1 dominant-negative/knockdown; Vps26/Vps35 inhibition; fluorescence microscopy of receptor recycling kinetics Traffic (Copenhagen, Denmark) Medium 20070609
2008 P2Y1 receptor constitutively dimerizes (44% of receptors as dimers at rest), with agonist exposure increasing dimerization to 85–100%; receptor dimers are required for internalization but not for activation. Removal of the C-terminal 19 amino acids abolished both dimerization and internalization; the last four amino acids (DTSL) mediate constitutive dimerization through binding to the scaffolding protein NHERF-2. FRET donor photobleaching in living HEK293 cells; C-terminal deletion mutants; functional assays for activation vs. internalization The Journal of biological chemistry High 18270199
2004 Membrane depolarization potentiates IP3-dependent Ca2+ mobilization by P2Y1 receptor in megakaryocytes via a voltage sensitivity intrinsic to the receptor itself (not voltage-gated Ca2+ channels, G-protein betagamma subunits, or downstream signals). Megakaryocytes from P2Y1-/- mice lacked voltage-dependent Ca2+ release during ADP stimulation. Whole-cell patch clamp combined with fura-2 fluorescence in megakaryocytes; nifedipine controls; P2Y1 knockout mice; dialysis with GTPgammaS and AlF4- The Journal of biological chemistry High 15528188
2001 P2Y1 receptor activation by 2-MeSADP stimulates ERK1/2 (EC50 ~5 nM) and selected SAPK/JNK isoforms but not p38 MAPK. Transient ERK activation involves cooperative effects of PI3K, Src, and PKC via Ras, while sustained ERK activation is Ras-independent and PI3K-dependent, culminating in Elk-1 phosphorylation. Transient SAPK activity via MKK4 is required for P2Y1-mediated apoptosis (caspase-3 activation). These responses are pertussis toxin-insensitive, indicating Gq-coupling. Selective kinase inhibitors; dominant-negative Ras and MKK4 mutants; pertussis toxin; phospho-specific Western blots; caspase-3 and cell number assays in stably expressing cells The Journal of biological chemistry High 11278310
2003 P2Y1 receptor activation by ATP in chick and mouse myotubes stimulates transcription of acetylcholinesterase and acetylcholine receptor subunit genes via a pathway involving PKC, intracellular Ca2+ release, ERK phosphorylation, and culminating in Elk-1 transcription factor activation. Two Elk-1 binding sites in the AChE promoter are sufficient to drive ATP-induced reporter gene transcription. Promoter-reporter constructs; dominant-negative and constitutively active kinase mutants; kinase inhibitors; gel mobility shift assays; nuclear phospho-Elk-1 immunostaining; P2Y1-selective antagonist blockade The Journal of neuroscience High 12805285
2006 Selective activation of P2Y1 receptors in astrocytes triggers glutamate release by regulated exocytosis. The mechanism requires Ca2+ release from internal stores and is controlled by TNFalpha and PGE2: P2Y1R activation induces release of both TNFalpha and PGE2, and blocking either one significantly reduces glutamate release. Astrocytes from TNFalpha-/- or TNFR1-/- mice show deficient P2Y1R-dependent Ca2+ signaling and glutamate release. TIRF imaging of fluorescent glutamatergic vesicles; calcium imaging; TNFalpha/TNFR1 knockout mice; cyclooxygenase inhibitors; P2Y1-selective pharmacology; acute hippocampal slices The Journal of biological chemistry High 16882655
2012 P2Y1 receptor (P2ry1) mediates the fast inhibitory junctional potential (fIJP) in murine colon via purinergic neurotransmission. P2ry1-/- mice completely lacked fIJPs and purinergic contractile responses. β-NAD and its metabolite ADPR caused P2Y1R-mediated hyperpolarization in wild-type but not P2ry1-/- mice. Colonic transit was significantly delayed in P2ry1-/- mice. P2ry1 knockout mice; electrophysiology (intracellular recordings); contractile experiments; picospritz neurotransmitter candidates; video imaging of colonic transit The Journal of physiology High 22371476
2014 Uridine adenosine tetraphosphate (Up4A) acts as a potent native agonist for P2Y1R in human and mouse colon muscles, causing relaxation and hyperpolarization via P2Y1R-SK channel activation. Up4A responses were blocked by MRS2500 and abolished in P2ry1-/- mice. Up4A induced MRS2500-sensitive Ca2+ transients in 1321N1 cells expressing human P2Y1R. P2ry1 knockout mice; isometric tension measurements; intracellular electrophysiology; isolated PDGFRα+ cells; heterologous expression calcium assays; HPLC metabolite analysis Proceedings of the National Academy of Sciences of the United States of America High 25341729
2003 P2Y1 receptor is involved in ADP-stimulated microglial cell migration, in addition to P2Y12. Pharmacological inhibition and siRNA knockdown of P2Y1 reduced ADP-stimulated microglial migration. TGF-β treatment increased P2Y1 and P2Y12 expression and ADP-induced migration, while LPS abrogated both receptor expression and migration. P2Y1/P2Y12 selective pharmacological inhibitors; P2Y1 siRNA knockdown; microglial migration assay; calcium mobilization assays; qPCR for receptor expression Journal of neurochemistry Medium 20681951
2005 P2Y1 receptor mediates ADP-induced Rac GTPase activation via Gq-dependent pathway in platelets, independently of P2Y12 and GPIIb/IIIa and PI3K. P2Y12 receptor alone cannot activate Rac per se, but secreted ADP potentiates Rac activation from other agonists via P2Y12. Rac activation by P2Y1 drives PAK activation and actin polymerization. Rac-GTP pulldown assay; selective P2Y1 and P2Y12 antagonists; P2Y1 knockout mice platelets; GPIIb/IIIa and PI3K inhibitors; PAK kinase assay; actin polymerization Journal of thrombosis and haemostasis High 16194206
2001 P2Y1 receptor mediates ADP-induced platelet shape changes including centralization of secretory granules, formation of filopodia, actin polymerization, and cytoskeletal translocation of cdc42, rac1, and rhoA in an integrin αIIbβ3-dependent manner. P2YT (P2Y12) receptor is required for stable macroaggregate formation and amplification of actin polymerization but not early platelet activation steps. Selective antagonists A2P5P (P2Y1) and AR-C67085 (P2Y12); electron microscopy; actin polymerization assay; subcellular fractionation for small GTPases Thrombosis and haemostasis Medium 11341507
2003 P2Y1 receptor-mediated Ca2+ signaling in astrocytes exhibits frequency-dependent negative feedback via protein kinase C, with high-frequency stimulation producing rapid Ca2+ oscillations. The PKC-dependent oscillation mechanism was mapped to Thr339 in the C-terminus of P2Y1R; mutation of this residue eliminated PKC-mediated negative feedback. Calcium imaging; PKC inhibitors; site-directed mutagenesis of P2Y1R C-terminal Thr339; frequency-dependent stimulation protocols in primary astrocytes The Journal of neuroscience Medium 12805284
2014 P2Y1 receptor in rat cortical astrocytes inhibits GABA transport (GAT-1 and GAT-3) by reducing transporter Vmax. This inhibition requires PLC activation and intracellular calcium release from stores, as it was blocked by PLC inhibitor U73122, BAPTA-AM (intracellular calcium chelation), and depletion of calcium stores with cyclopiazonic acid. P2Y1-selective agonist (2-MeSADP) and antagonist (MRS2179); GABA transport kinetics (Vmax/Km); PLC inhibitor; BAPTA-AM; calcium store depletion; primary astrocyte cultures Glia Medium 24733747
2015 P2Y1 receptor activation in satellite glial cells (SGCs) couples to and activates TRPV4 ion channel through PKC. P2Y1-selective agonist (2-MeSADP) increased [Ca2+]i in SGCs expressing TRPV4, and responses were enhanced in TRPV4-expressing HEK293 cells; PKC inhibitors prevented P2Y1 receptor activation of TRPV4. Calcium imaging in isolated DRG neurons with attached SGCs; TRPV4 knockout mice; P2Y1-selective agonist/antagonist; PKC inhibitors; HEK293 co-expression The Journal of biological chemistry Medium 26475857
2004 NTPDase1 co-localizes with P2Y1 receptor in caveolae of human placental endothelial cells, and enzymatic activity of NTPDase1 controls the local concentration of ADP/ATP available to activate P2Y1R. In NTPDase1-/- mice, P2Y1 receptor-dependent endothelial relaxation is dramatically enhanced (EC50 for ADP shifted from 14 µM to 0.35 µM) and P2Y1 receptors become more extensively desensitized. Immunohistochemistry and immuno-electron microscopy of human placenta; NTPDase1 knockout mice; vascular ring relaxation assays; in vivo blood pressure measurements European journal of histochemistry; British journal of pharmacology Medium 15590415 20067476
2004 NTPDase1 coexpression dramatically reduces P2Y1 receptor activation potency (50-fold increase in EC50 for ADP), while NTPDase2 increases apparent ATP potency at P2Y1R by converting ATP to ADP. Basal P2Y1 receptor activity is maintained by paracrine/autocrine nucleotide release and is abolished by NTPDase1. Co-expression of NTPDase1 or NTPDase2 with P2Y1R in same cell or co-culture; phospholipase C activity assays; comparison of agonist EC50 values Molecular pharmacology Medium 15496502
2014 RhoA signaling downstream of platelet P2Y1 receptor (not P2Y12 or P2X1) mediates platelet-dependent leukocyte recruitment in allergic inflammation. P2Y1 receptor stimulation activated RhoA in vivo after allergen challenge, and ROCK1 inhibition in platelets phenocopied P2Y1 antagonism in preventing platelet-dependent leukocyte chemotaxis. Selective P2Y1 antagonist in ovalbumin-sensitized BALB/c mice; thrombocytopenia reinfusion experiments with P2Y1-antagonist or ROCK1-inhibitor pretreated platelets; RhoA activity assays; bronchoalveolar lavage cell counts The Journal of allergy and clinical immunology Medium 25445826
2008 ADP stimulates human endothelial cell migration via P2Y1 receptor-mediated activation of ERK1/2, JNK, and p38 MAPK pathways. Blockade of ERK or JNK (but partial inhibition with p38 blockade) abolished ADP/2-MeSADP-stimulated HUVEC migration. This was blocked by MRS2179 (P2Y1 antagonist) but not AR-C69931MX (P2Y12/13 antagonist). Boyden chamber and wound-repair migration assays; RT-PCR for receptor expression; phospho-specific Western blots; selective MAPK inhibitors (U0126, SP600125, SB203580); selective P2Y1 antagonist Circulation research Medium 18174464
2007 P2Y1 receptor in epithelial cells transactivates EGFR to broadcast mitogenic signals via PKC, Src, and cell surface metalloproteases. P2Y1R stimulation for 15–60 min triggered proliferation; apyrase degradation of extracellular nucleotides or P2Y1R drug inhibition reduced basal cell proliferation. MDCK cells ectopically expressing P2Y1R showed a highly proliferative EGFR-dependent phenotype with increased EGFR levels. Apyrase treatment; P2Y1R pharmacological inhibition; ectopic P2Y1R expression in MDCK cells; PKC/Src/metalloprotease inhibitors; cell proliferation assays Journal of cell science Medium 18057028
2008 P2Y1 receptor signaling in pancreatic beta cells contributes to glucose-induced pulsatile insulin secretion through autocrine activation following ATP exocytosis, generating plasma membrane DAG spikes in spatially confined microdomains. Each DAG spike causes local PKC activation and MARCKS dissociation from the plasma membrane. Inhibition of P2Y1 suppressed glucose-induced pulsatile insulin secretion. TIRF microscopy with DAG/PKC translocation biosensors; insulin secretion assay; P2Y1/P2X receptor inhibitors; exocytosis inhibition; MIN6 cells, primary mouse, and human beta cells FASEB journal Medium 23299857
2013 Polyphosphate amplifies proinflammatory responses of histone H4 and HMGB1 specifically through RAGE and P2Y1 receptor interaction in human umbilical vein endothelial cells, eliciting intracellular Ca2+ release. siRNA knockdown of P2Y1 and extracellular domain competitive inhibition demonstrated P2Y1 is required for polyP-mediated H4/HMGB1 inflammatory signaling. siRNA knockdown of TLR2, TLR4, RAGE, P2Y1; competitive inhibition with extracellular receptor domains; calcium release assays; in vivo inflammatory models Blood Medium 24255918
2003 P2Y12 receptor (not P2Y1) is involved in thrombin-induced phosphatidylserine (PS) exposure on platelets and subsequent TF-induced thrombin generation in platelet-rich plasma. Both P2Y1 and P2Y12 contribute to platelet-leukocyte interactions and leukocyte TF exposure via P-selectin. Selective P2 antagonists MRS2179 (P2Y1) and AR-C69931MX (P2Y12); PS exposure assay; thrombin generation in platelet-rich plasma; platelet-leukocyte complex formation Arteriosclerosis, thrombosis, and vascular biology Medium 12933533
2003 P2Y1 receptor mediates ADP-induced p38 MAP kinase-activating factor generation in human platelets. The P2Y1-selective antagonist A2P5P inhibited ADP-induced p38 kinase activation in a concentration-dependent manner, while the P2TAC (P2Y12) antagonist AR-C66096 did not, and P2X1-selective agonist alphabeta-meATP failed to activate p38. Selective P2Y1 antagonist (A2P5P) and P2Y12 antagonist (AR-C66096); p38 MAP kinase phosphorylation assay; aspirin-treated vs normal platelets; TX synthase inhibitor controls European journal of biochemistry Medium 10759852
2011 P2Y1 receptor is required for normal thermal sensitivity in cutaneous polymodal nociceptors (CPMs). P2Y1-/- mice showed significantly increased heat thresholds and decreased peak firing rates during thermal ramp stimulation, and altered cold thresholds, with no significant change in mechanical sensitivity. Most ADP-responsive DRG neurons co-express IB4 binding and P2X3. P2Y1 knockout mice; ex vivo skin-nerve-DRG-spinal cord recording preparation; ratiometric calcium imaging of isolated DRG neurons; digital thermal and mechanical stimuli Molecular pain High 21310055
2011 Inflammation-induced upregulation of P2Y1 receptor in DRG neurons is required for CFA-induced heat sensitization of cutaneous CPM fibers. siRNA knockdown of the P2Y1 increase during inflammation completely blocked the normal reduction of heat thresholds. P2Y1 knockdown also increased TRPV1-expressing CPM neurons without changing total TRPV1+ cells, indicating P2Y1 maintains phenotype in cutaneous TRPV1-negative afferents. In vivo siRNA knockdown targeting DRG P2Y1; CFA-induced inflammation; ex vivo electrophysiological recording; immunohistochemistry for TRPV1 expression Pain Medium 22137295
2003 Reduced P2Y1 receptor expression in Cx43-null neural progenitor neurospheres impairs calcium signaling in response to P2Y (but not P2X) agonists, and reduces proliferation and migration of neural progenitors. Ectopic expression of P2Y1R in Cx43-null cells restored migration to wild-type levels. Connexin43 knockout mice-derived neurospheres; pharmacological blockade with MRS-2179 and suramin; P2Y1R rescue by ectopic expression; calcium imaging; BrdU proliferation assay; migration assay The Journal of neuroscience Medium 14673009
2017 BPTU (allosteric P2Y1R antagonist binding outside the helical bundle) antagonizes P2Y1R in a pattern that varies by signaling pathway and agonist used: surmountable (parallel rightward shift, unaffected Emax) for ERK1/2 and label-free readouts with 5'-diphosphate agonists, but insurmountable (suppressed Emax) for GTPgammaS binding and beta-arrestin2 recruitment, and insurmountable in all pathways with dinucleotide Ap4A. Orthosteric MRS2500 behaves as surmountable antagonist across all pathways and agonists. Multiple signaling assays (ERK1/2, GTPgammaS binding, beta-arrestin2 recruitment, label-free dynamic mass redistribution); concentration-response curve analysis with diverse agonists Molecular pharmacology Medium 28864555
2008 Mechanical stress in human periodontal ligament cells induces ATP release, which activates P2Y1 receptor to stimulate Rho kinase activation and subsequent osteopontin (OPN) expression upregulation. Selective P2Y1 antagonist MRS2179 and apyrase abolished stress-induced OPN expression. Mechanical stress stimulation; P2Y1 antagonist (MRS2179); apyrase; Rho kinase inhibitor; RT-PCR and Western blot for OPN Journal of dental research Medium 18502966
2010 Extracellular ATP stimulates RANKL expression in human periodontal ligament cells through P2Y1 receptor via a COX-dependent pathway involving cAMP-dependent PKA, NF-κB activation, and prostaglandin E2 production. P2Y1 siRNA and the selective antagonist MRS2179 both diminished this effect. P2Y1 siRNA; selective antagonist MRS2179; COX inhibitor indomethacin; PKA inhibitor H89; NF-κB inhibitor; PGE2 ELISA; RANKL RT-PCR and Western blot Journal of periodontal research Medium 20337886
2007 A1 adenosine receptor and P2Y1 receptor co-localize at synaptic membranes and surrounding astroglial membranes of glutamatergic synapses in rat hippocampus. Functionally, P2Y1 receptor stimulation impairs A1 receptor coupling to G protein, while A1 receptor stimulation increases P2Y1 receptor functional responsiveness. Postembedding immunogold electron microscopy; G protein coupling assays after receptor co-stimulation in hippocampal tissue The European journal of neuroscience Medium 17672857

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 288 25822790
1997 The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS letters 239 9038354
1996 Identification of competitive antagonists of the P2Y1 receptor. Molecular pharmacology 225 8913364
1998 The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation. Blood 206 9639511
2006 P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor-alpha and prostaglandins. The Journal of biological chemistry 177 16882655
1998 Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. Journal of medicinal chemistry 140 9554879
2017 LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell death and differentiation 137 28644440
2005 P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 133 15665114
1998 ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Molecular pharmacology 117 9547364
2003 Localisation of P2Y1 and P2Y4 receptors in dorsal root, nodose and trigeminal ganglia of the rat. Histochemistry and cell biology 115 14564529
1996 Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochemical and biophysical research communications 115 8579591
1998 Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. Journal of medicinal chemistry 111 9457242
2003 Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arteriosclerosis, thrombosis, and vascular biology 108 12933533
2003 Reduced expression of P2Y1 receptors in connexin43-null mice alters calcium signaling and migration of neural progenitor cells. The Journal of neuroscience : the official journal of the Society for Neuroscience 106 14673009
2012 P2Y1 purinoreceptors are fundamental to inhibitory motor control of murine colonic excitability and transit. The Journal of physiology 104 22371476
2004 Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arteriosclerosis, thrombosis, and vascular biology 100 15514209
2004 Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Molecular pharmacology 98 14742685
2018 P2Y1 receptor blockade normalizes network dysfunction and cognition in an Alzheimer's disease model. The Journal of experimental medicine 96 29724785
2013 Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood 96 24255918
2001 Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis. The Journal of biological chemistry 91 11278310
1998 P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors. British journal of pharmacology 89 9630355
2010 TGF-β and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. Journal of neurochemistry 86 20681951
2003 P2X4, P2Y1 and P2Y2 receptors on rat alveolar macrophages. British journal of pharmacology 82 12970084
1996 Cloning and tissue distribution of the human P2Y1 receptor. Biochemical and biophysical research communications 82 8630005
2008 Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. The Biochemical journal 81 17824841
2018 Glutamate-induced and NMDA receptor-mediated neurodegeneration entails P2Y1 receptor activation. Cell death & disease 76 29463792
2003 Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 73 12805284
2008 ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. Circulation research 72 18174464
2016 Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia. Oncogene 66 26973243
2008 A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation. Blood 64 18596227
2003 ATP acts via P2Y1 receptors to stimulate acetylcholinesterase and acetylcholine receptor expression: transduction and transcription control. The Journal of neuroscience : the official journal of the Society for Neuroscience 64 12805285
2014 RhoA signaling through platelet P2Y₁ receptor controls leukocyte recruitment in allergic mice. The Journal of allergy and clinical immunology 60 25445826
2004 Expression of P2Y1, P2Y2, P2Y4, and P2Y6 receptor subtypes in the rat retina. Investigative ophthalmology & visual science 60 15452043
2000 Expression of purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11) during myeloid differentiation of HL60 cells. Biochimica et biophysica acta 58 11004484
2001 Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. Journal of medicinal chemistry 57 11543678
2009 Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 56 19637098
2005 P2Y1 and cysteinyl leukotriene receptors mediate purine and cysteinyl leukotriene co-release in primary cultures of rat microglia. International journal of immunopathology and pharmacology 56 15888248
1999 Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. Journal of medicinal chemistry 56 10229631
2010 P2Y1 and P2Y13 purinergic receptors mediate Ca2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells. American journal of physiology. Cell physiology 51 20962269
2004 Direct voltage control of signaling via P2Y1 and other Galphaq-coupled receptors. The Journal of biological chemistry 51 15528188
2000 Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease. Neuroreport 51 11117494
1998 ATP-induced arachidonic acid release in cultured astrocytes is mediated by Gi protein coupled P2Y1 and P2Y2 receptors. Glia 51 9517568
2016 ALIX Regulates the Ubiquitin-Independent Lysosomal Sorting of the P2Y1 Purinergic Receptor via a YPX3L Motif. PloS one 50 27301021
2009 Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca2+ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation. Thrombosis and haemostasis 50 20024498
2018 P2RY1/ALK3-Expressing Cells within the Adult Human Exocrine Pancreas Are BMP-7 Expandable and Exhibit Progenitor-like Characteristics. Cell reports 48 29490276
2008 Mechanical stress induces osteopontin via ATP/P2Y1 in periodontal cells. Journal of dental research 48 18502966
2003 Characterization of P2X3, P2Y1 and P2Y4 receptors in cultured HEK293-hP2X3 cells and their inhibition by ethanol and trichloroethanol. Journal of neurochemistry 48 12694404
2003 The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovascular drug reviews 47 12595918
2016 The Molecular Mechanism of P2Y1 Receptor Activation. Angewandte Chemie (International ed. in English) 46 27460867
2010 Regulation of P2Y1 receptor traffic by sorting Nexin 1 is retromer independent. Traffic (Copenhagen, Denmark) 46 20070609
2004 Expression of P2Y1 receptors in rat taste buds. Histochemistry and cell biology 45 15103469
2001 Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation. Thrombosis and haemostasis 45 11341507
2014 P2Y1 receptor inhibits GABA transport through a calcium signalling-dependent mechanism in rat cortical astrocytes. Glia 44 24733747
2013 P2Y₁ receptor-dependent diacylglycerol signaling microdomains in β cells promote insulin secretion. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 43 23299857
2007 Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells. Journal of cell science 43 18057028
2006 P2Y1 and P2X7 receptors induce calcium/calmodulin-dependent protein kinase II phosphorylation in cerebellar granule neurons. The European journal of neuroscience 43 16819989
2020 LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2. Cancer biomarkers : section A of Disease markers 42 32508321
2015 P2Y1 Receptor Activation of the TRPV4 Ion Channel Enhances Purinergic Signaling in Satellite Glial Cells. The Journal of biological chemistry 42 26475857
2007 Co-localization and functional cross-talk between A1 and P2Y1 purine receptors in rat hippocampus. The European journal of neuroscience 42 17672857
2014 Participation of peripheral P2Y1, P2Y6 and P2Y11 receptors in formalin-induced inflammatory pain in rats. Pharmacology, biochemistry, and behavior 41 25449358
2000 The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. European journal of biochemistry 41 10759852
2011 Purinergic receptor P2Y1 regulates polymodal C-fiber thermal thresholds and sensory neuron phenotypic switching during peripheral inflammation. Pain 40 22137295
2010 The ecto-nucleotidase NTPDase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation. British journal of pharmacology 40 20067476
2006 Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochemical pharmacology 40 16934758
2005 A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. Journal of thrombosis and haemostasis : JTH 40 16194206
2011 Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochemical pharmacology 39 21632028
2008 Effects of P2Y1 receptor on glial fibrillary acidic protein and glial cell line-derived neurotrophic factor production of astrocytes under ischemic condition and the related signaling pathways. Neuroscience bulletin 38 18668152
2019 Context-Specific Switch from Anti- to Pro-epileptogenic Function of the P2Y1 Receptor in Experimental Epilepsy. The Journal of neuroscience : the official journal of the Society for Neuroscience 37 31048325
2018 Role of Purinergic Receptor P2Y1 in Spatiotemporal Ca2+ Dynamics in Astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 36 29305530
2001 P2y1 and P2y2 receptor-operated Ca2+ signals in primary cultures of cardiac microvascular endothelial cells. Microvascular research 35 11336535
2008 P2Y1 receptor-mediated glutamate release from cultured dorsal spinal cord astrocytes. Journal of neurochemistry 34 18627435
2016 P2Y1 Receptor Signaling Contributes to High Salt-Induced Priming of the NLRP3 Inflammasome in Retinal Pigment Epithelial Cells. PloS one 33 27788256
2014 Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut. Proceedings of the National Academy of Sciences of the United States of America 33 25341729
2012 Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets 33 22721490
2016 Dual Modulation of Nociception and Cardiovascular Reflexes during Peripheral Ischemia through P2Y1 Receptor-Dependent Sensitization of Muscle Afferents. The Journal of neuroscience : the official journal of the Society for Neuroscience 32 26740646
1999 Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. Biochemical and biophysical research communications 32 10066429
2010 The purinergic P2Y1 receptor supports leptin secretion in adipose tissue. Endocrinology 31 20185765
2008 Novel consequences of voltage-dependence to G-protein-coupled P2Y1 receptors. British journal of pharmacology 31 18414379
2008 Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Combinatorial chemistry & high throughput screening 31 18673269
2004 Regulation of P2Y1 receptor-mediated signaling by the ectonucleoside triphosphate diphosphohydrolase isozymes NTPDase1 and NTPDase2. Molecular pharmacology 31 15496502
2003 Enhanced P2Y1 receptor expression in the brain after sensitisation with d-amphetamine. Psychopharmacology 31 12652343
2017 Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor. Molecular pharmacology 30 28864555
2012 Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands. The Journal of pharmacology and experimental therapeutics 30 22991416
2004 Subtype specific internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-boranotriphosphate) derivatives. British journal of pharmacology 30 15197109
1997 Changes in P2Y1 nucleotide receptor activity during the development of rat salivary glands. The American journal of physiology 30 9142866
2010 Adenosine triphosphate stimulates RANKL expression through P2Y1 receptor-cyclo-oxygenase-dependent pathway in human periodontal ligament cells. Journal of periodontal research 29 20337886
2006 The enteric purinergic P2Y1 receptor. Current opinion in pharmacology 29 16934527
2008 Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. The Journal of biological chemistry 28 18270199
2007 P2Y1 gene deficiency protects from renal disease progression and capillary rarefaction during passive crescentic glomerulonephritis. Journal of the American Society of Nephrology : JASN 28 17215444
2004 Co-localization of P2Y1 receptor and NTPDase1/CD39 within caveolae in human placenta. European journal of histochemistry : EJH 28 15590415
2016 The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys. Journal of thrombosis and thrombolysis 27 26660522
2012 P2Y1 purinoceptor inhibition reduces extracellular signal-regulated protein kinase 1/2 phosphorylation in spinal cord and dorsal root ganglia: implications for cancer-induced bone pain. Acta biochimica et biophysica Sinica 27 22349022
2010 P2Y1 receptors mediate apamin-sensitive and -insensitive inhibitory junction potentials in murine colonic circular smooth muscle. The Journal of pharmacology and experimental therapeutics 27 20103587
2006 Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues. British journal of pharmacology 27 16953187
2007 Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells. The Journal of pharmacology and experimental therapeutics 26 17626796
2006 P2Y1 and P2Y2 receptor distribution varies along the human placental vascular tree: role of nucleotides in vascular tone regulation. The Journal of physiology 26 16543271
2019 MiR-34b-3p Represses the Multidrug-Chemoresistance of Bladder Cancer Cells by Regulating the CCND2 and P2RY1 Genes. Medical science monitor : international medical journal of experimental and clinical research 25 30778022
2014 Differential effects of P2Y1 deletion on glial activation and survival of photoreceptors and amacrine cells in the ischemic mouse retina. Cell death & disease 24 25077539
2011 The ADP receptor P2Y1 is necessary for normal thermal sensitivity in cutaneous polymodal nociceptors. Molecular pain 24 21310055
2009 P2X2, P2X4 and P2Y1 receptors elevate intracellular Ca2+ in mouse embryonic stem cell-derived GABAergic neurons. British journal of pharmacology 24 20050186

Missed literature

Know a paper Affinage missed for P2RY1? Flag it for the maintainers and the community.

No submissions yet.